Goldman Sachs’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Goldman Sachs’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-13,771	Closed	-$36K	–	5660
2020 Q1	$36K	Sell	13,771 -44,043	-76%	-$72.2K	﹤0.01%	5084
2019 Q4	$68K	Buy	57,814 +12,396	+27%	+$19.8K	﹤0.01%	5093
2019 Q3	$78K	Sell	45,418 -6,332	-12%	-$19.3K	﹤0.01%	4993
2019 Q2	$245K	Buy	51,750 +21,373	+70%	+$120K	﹤0.01%	4697
2019 Q1	$196K	Buy	30,377 +14,790	+95%	+$77.4K	﹤0.01%	4809
2018 Q4	$78K	Buy	+15,587	New	+$109K	﹤0.01%	5041
2018 Q3	–	Sell	-62,500	Closed	-$788K	–	5921
2018 Q2	$788K	Buy	+62,500	New	+$856K	﹤0.01%	4233

Goldman Sachs's NTGN Position: Q2 2020 in Review

Goldman Sachs sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 13,771 shares — an estimated $36K sold.

Goldman Sachs first reported a position in NTGN in Q2 2018 and held it in 7 quarters. The position peaked at $788K in Q2 2018. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

Goldman Sachs reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Goldman Sachs sold 13,771 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $36K.
Goldman Sachs first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 7 quarters.
Goldman Sachs's Neon Therapeutics, Inc. Common Stock position peaked at $788K in Q2 2018.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Goldman Sachs's 13F filing for Q2 2020, filed 12 Aug 2020.